Supporting the Biggest Brands in Advanced Therapies

We empower leading brands to elevate their visibility and engagement, turning potential leads into devoted customers and champions throughout their commercial journey. As a comprehensive content marketing ally for the advanced therapies market, we offer strategic insights, expert consultation, tailored content creation, and wide distribution. Our commitment to educating the advanced therapies community has ingrained in us the power of impactful content. Today, we pave the way for the foremost brands in advanced therapies to share their narratives and forge trusted bonds through content.

Your content marketing agency for Advanced Therapies

Past Webinars


Workshop: A Design Team’s Views on Optimizing your Viral Vector for Clinical Success

A discussion on the design, development and optimization of lentiviral vectors and accelerate your pathway to the clinic.
Thursday, August 24, 2023 | 11:00 [EDT] | 08:00 [PDT] | 16:00 [BST]

Unlock the Future of Advanced Therapeutics: Considerations for Developing Global Manufacturing Capacity

Join the discussion of what to consider when developing a global manufacturing capacity
Thursday, July 27, 2023 | 11:00 [EDT] | 08:00 [PDT] | 16:00 [BST]

Addressing Disparities in Access to Cell and Gene Therapies

Join the discussion addressing disparities in access to cell and gene therapies
Thursday, August 10, 2023 | 11:00 [EDT] | 08:00 [PDT] | 16:00 [BST]
Our eBooks
The Phacilitate team is delighted to present this eBook, in partnership with WuXi Advanced Therapies, as a comprehensive resource for gene therapy development.
Advanced therapies’ market access is a hot topic. Joining Phacilitate to shed some light on market access struggles are Director at NJ Redfern Limited and ex-bluebird bio UK GM Nicola Redfern, former SVP & CBO at Novartis Gene Therapies and current AviadoBio CEO Lisa Deschamps, and, Vice President and Global Head of Value and Access, at Novartis, Tay Salimullah.
What’s preventing developers from designing mechanistically relevant assays? This report examines this question, focusing on the identification and measurement of appropriate CQAs, the value of fit-for-purpose analytics technologies and what the future of CGT manufacturing analytics should look like.
Exploring digital solutions for cell and gene therapy manufacturing: a Pharma 4.0 perspective.